266 related articles for article (PubMed ID: 21209860)
1. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
[TBL] [Abstract][Full Text] [Related]
2. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
4. DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors.
Edfeldt K; Daskalakis K; Bäcklin C; Norlén O; Tiensuu Janson E; Westin G; Hellman P; Stålberg P
Neuroendocrinology; 2017; 105(2):170-181. PubMed ID: 27829249
[TBL] [Abstract][Full Text] [Related]
5. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
6. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
[No Abstract] [Full Text] [Related]
7. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
8. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
9. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
11. The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression.
Filosso PL; Kidd M; Roffinella M; Lewczuk A; Chung KM; Kolasinska-Cwikla A; Cwikla J; Lowczak A; Doboszynska A; Malczewska A; Catalano M; Zunino V; Boita M; Arvat E; Cristofori R; Guerrera F; Oliaro A; Tesselaar M; Buikhuisen W; Kos-Kudla B; Papotti M; Bodei L; Drozdov I; Modlin I
Eur J Cardiothorac Surg; 2018 Mar; 53(3):631-639. PubMed ID: 29145657
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
13. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
[TBL] [Abstract][Full Text] [Related]
14. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
15. [Anti-Ma2-associated encephalitis and paraneoplastic limbic encephalitis].
Yamamoto T; Tsuji S
Brain Nerve; 2010 Aug; 62(8):838-51. PubMed ID: 20714032
[TBL] [Abstract][Full Text] [Related]
16. A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.
Kjellman M; Knigge U; Welin S; Thiis-Evensen E; Gronbaek H; Schalin-Jäntti C; Sorbye H; Joergensen MT; Johanson V; Metso S; Waldum H; Søreide JA; Ebeling T; Lindberg F; Landerholm K; Wallin G; Salem F; Schneider MDP; Belusa R
Neuroendocrinology; 2021; 111(9):840-849. PubMed ID: 32721955
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity and Specificity of the NETest: A Validation Study.
Al-Toubah T; Cives M; Valone T; Blue K; Strosberg J
Neuroendocrinology; 2021; 111(6):580-585. PubMed ID: 32615553
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis.
Rossi RE; Ciafardini C; Sciola V; Conte D; Massironi S
Pancreas; 2018; 47(10):1249-1255. PubMed ID: 30325865
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies.
Molina R; Alvarez E; Aniel-Quiroga A; Borque M; Candás B; Leon A; Poyatos RM; Gelabert M
Tumour Biol; 2011 Feb; 32(1):13-22. PubMed ID: 20730520
[TBL] [Abstract][Full Text] [Related]
20. Cell-Free DNA and Clinical Characteristics in Patients with Small Intestinal or Pancreatic Neuroendocrine Tumors.
Oversoe SK; Sorensen BS; Tabaksblat EM; Gronbaek H; Kelsen J
Neuroendocrinology; 2022; 112(1):43-50. PubMed ID: 33461190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
